Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in ...

Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective ...

A study, published in Basic Research in Cardiology, demonstrates in an experimental model that the heart can be protected during anthracycline treatment using a simple, non-pharmacological technique ...

Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –– Reduced secured and convertible debt by 90% from ...

Al-Aly and his colleagues found that people starting the GLP-1 drugs had lower risks of developing addiction to multiple ...

Brebeuf girls' basketball coach Erin Miller did not know if she could make it through season after cancer diagnosis. She ...

HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...

Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective anticancer drugs—a class ...

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced ...